Cobert's Manual Of Drug Safety And Pharmacovigilance (Third Edition). William Gregory
yet, and genomics is barely mentioned in this book. With luck, we will see significant contributions to public health as our medical knowledge increases. The paradigms (sorry for the use of that word, but it fits) are changing: it is now “benefit–risk,” “quality management systems,” and “risk aversion.” These words and concepts were hardly used in medicine 50 years ago. Next, drug safety has gone global. It is quaint to think that the International Conference on Harmonization, which began in 1989, included all the major players in the field: the United States, Europe (actually just three or four major western European countries), and Japan, with a few silent observers. Drug safety is now global, in large part because of the Uppsala Monitoring Centre, with new and vibrant ideas coming from all over the world.
On the disheartening side, we see corporatization, digitalization, depersonalization, politicization, commoditization, and other “-izations” in drug safety and medicine in general. Medicine is now a mass-market commodity, and drug safety is following that path too. We see laxity and bad behavior on the part of industry, healthcare practitioners, patients, consumers, government, universities, and non-governmental organizations. We see politics and money continue to play a big role in the world of pharmacology. We also see the downside of globalization, with enormous fragmentation and duplication of efforts, and little upside. Add to this the “human condition” of wanting a magic pill to allow us to eat, drink, smoke, and do other things to our heart’s content without damage to our health.
A suggestion: There are two major uses for this manual. The first is as a textbook for those who wish to learn the field or review their knowledge of drug safety. Those folks may wish to read the book cover to cover (on their own or as part of a course) or the parts they need to brush up on. The second is as a reference. For this, I would highly suggest loading the manual onto your PC, Mac, iPhone, iPad, Android, or other techno-marvel and using a PDF search tool (e.g., in Adobe) for the key word or concept you are looking for. Although I have attempted to keep concepts in their dedicated chapters, many ideas (e.g., causality determinations) must be discussed in multiple chapters. Using a PDF search will quickly get you to the right place in the text.
There it is. I hope you find the book useful, accurate, and easy to read and absorb. Best of luck. You’ll need it.
This is now the third edition of this manual. You will notice several things.
First, we now have three authors not just one. The field has become so complex, diverse, global and messy that it is impossible for one person to be fully versed in the field to do a single author textbook.
Second, we have eliminated some country specific chapters and removed other chapters or details which are now out of date (e.g. the three 2005 FDA guidances on risk). Obviously, no slight is intended to those countries which are not discussed in this edition. Rather we have chosen to focus on the US and the European Union where the bulk (we believe) of our readers have been found and which, realistically, play pivotal roles in pharmacovigilance and drug safety.
The field is changing so rapidly that it is hard to even keep up with the changes in the US, EU and EU member states let alone the many other nations now doing drug safety.
The special and extraordinary case of the United Kingdom’s leaving the EU (Brexit) has put us in a quandary. This manual was written in the midst of the negotiations between the UK and the EU. Things have been and will clearly continue to change for the UK and the EU/member states as the EMA moves out of the UK to the Netherlands. We made a practical decision to leave out much of the UK/MHRA information fully realizing this is a major loss. We felt that whatever we said when the material was written would surely change by the time you read this.
Third, the field of DS and PV has continued to evolve. There is now a much greater emphasis on analysis of risk and toxicities in drug safety rather than an emphasis on collection of data (“filling in all the boxes”). Health agencies and “pharmacovigilantes” (a humorous term referring to people working in the field of drug safety) emphasize more and more that risk analysis and the minimization of toxicity and risk are the major goals of PV. Given the extraordinary changes in IT and data collection, it is now presumed by the health agencies that global data can and will be accurately and completely collected and processed both in clinical trials and in the post-marketing setting. With changes in approval procedures for marketing we are now seeing drugs reach the market with fewer patients studied and less known about the safety profile. We are also seeing more post-marketing requirements. This may or may not be a good thing.
Other major changes include the divergences in many areas that were more or less harmonized by ICH. Harmonization seems to have peaked in the early 2000s. We now see divergences in the US and EU and in many other areas. ISO has entered the picture and many more countries and outside organizations are now involved in the pharmaceutical world. Hopefully these are good things.
The downside of the manual seems to be largely unchanged from the notes in the introduction to the second edition:
“On the disheartening side, we see corporatization, digitalization, depersonalization, politicization, commoditization, and other “-izations” in drug safety and medicine in general. Medicine is now a mass-market commodity, and drug safety is following that path too. We see laxity and bad behavior on the part of industry, healthcare practitioners, patients, consumers, government, universities, and nongovernmental organizations. We see politics and money continue to play a big role in the world of pharmacology. We also see the downside of globalization, with enormous fragmentation and duplication of efforts, and little upside.”
Several housekeeping comments:
So, to conclude, with all the changes underway in the world both in general and in the pharmaceutical PV arenas, we need to keep in mind that the goal of DS and PV remains rather simple and straightforward: protect the patients and minimize toxicity and risk from medications.
Whether we are making progress in this area is hard to know.
The last sentence from the second edition introduction also remains valid:
“There it is. We hope you find the book useful, accurate, and easy to read and absorb. Best of luck. You’ll need it.”
Contributors
Lisa Beth Ferstenberg, MD
Chief Medical Officer, Praxis Scientific, Washington DC
(Author of Chapter 41 Vaccinovigilance)
Germano Ferreira, PharmD, PhD
Consultant, Epidemiologist and Senior Real World Data Scientist.
(Reviewer of Chapters 5 (Mathematics of AE) and 6 (Pharmacoepidemiology)
Notice
This book is not meant to be used in the practice of medicine or for the prescription of medicines, drugs, biologics, over-the-counter medications, health foods, supplements, and so forth. The medications described do not necessarily have specific approval by the U.S. Food and Drug Administration, European Medicines Agency, Health Canada, or any other regulatory or health agency for use in the diseases, patients, or dosages discussed. The approved labeling in the United States and other countries